Revimmune cyclophosphamide autoimmune data

Data from 140 patients with various refractory autoimmune diseases including multiple sclerosis (MS) and systemic lupus erythematosus (SLE) showed that 50 mg/kg/day Revimmune for 4 days produced an ORR of 94% with 44% of responders remaining progression-free at a median follow-up of 36 months. Additionally, rates of OS and EFS at 60 months were 90.7% and 20.6%, respectively. Revimmune was well tolerated. Data were published in Medicine. ...